This SELECT prespecified analysis showed that semaglutide reduces total hospital admissions and length of stay in patients with obesity and established cardiovascular disease, demonstrating healthcare utilization benefits beyond cardiovascular event reduction.
This prespecified exploratory analysis of the SELECT randomized clinical trial determines the impact of semaglutide on total hospital admissions and duration of hospital stay.
